You are here

Structural & Congenital Heart Disease

 

A recent article in Cardiovascular Business summarized the lack of quality research on surgeries for children with congenital heart disease.

New-generation devices have made transcatheter aortic valve replacements (TAVRs) easier to perform in patients with pure native aortic regurgitation (AR), suggests a study published in the Journal of the American College of Cardiology.

Infant deaths from critical congenital heart disease (CCHD) declined by 33.4 percent in eight states that mandated pulse oximetry screening for newborns, according to a study published online Dec. 5 in JAMA.

Multidetector computed tomography (CT) could play a pivotal role in improving the outcomes of transcatheter aortic valve replacement (TAVR) procedures, research presented at the 103rd annual RSNA symposium suggests.

The mortality risk associated with moderate to severe PVR was consistent with previous studies, wrote lead author Phillippe Pibarot, DVM, PhD, and colleagues, but the rate of moderate or worse PVR dropped threefold when compared to previous SAPIEN valves.

 

Recent Headlines

Intel co-founder, wife donate $50 million for children’s hospital at Stanford

Gordon and Betty Moore donated $50 million to the Lucille Packard Children’s Hospital Stanford in Palo Alto, California, the largest private gift the hospital received since David and Lucille Packard’s donation to found the hospital.

Boston Scientific acquires privately held TAVR company for $435 million

Boston Scientific agreed to acquire Symetis SA on March 30 for $435 million in an all-cash deal.

ACC.17: Subclinical leaflet thrombosis occurs more often in TAVR versus SAVR patients

Subclinical leaflet thrombosis occurred in 13.6 percent of patients undergoing transcatheter aortic valve replacement (TAVR) and 3.8 percent of patients undergoing surgical aortic valve replacement (SAVR), according to an analysis of two registries.

FDA approves the CoreValve Evolut PRO TAVR valve for high or extreme risk patients

The FDA approved the CoreValve Evolut PRO valve for transcatheter aortic valve replacement (TAVR) in patients with severe, symptomatic aortic stenosis who are at high or extreme risk for open heart surgery.

ACC.17: SURTAVI trial finds TAVR, SAVR have similar all-cause mortality rates at 24 months

After two years, intermediate-risk patients with severe symptomatic aortic stenosis had similar rates of all-cause mortality or disabling stroke whether they underwent transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR), according to a randomized trial.

FDA expands approval of the Melody transcatheter pulmonary valve

The FDA approved the Melody transcatheter pulmonary valve for patients whose surgical bioprosthetic pulmonary heart valves failed.

Mayo Clinic, Children’s Hospital of Philadelphia collaborate on congenital heart disease program

The Mayo Clinic and the Children’s Hospital of Philadelphia are working together to delay and prevent heart failure from hypoplastic left heart syndrome (HLHS), a rare and complex form of congenital heart disease in children.

Courts in Germany, UK rule in Boston Scientific’s favor in TAVR patent cases

Courts in Germany and the United Kingdom have ruled that Edwards Lifesciences infringed on patents related to Boston Scientific’s transcatheter heart valves.

Natural protein could prevent damage from heart disease, heart attacks

A new study from San Diego State University (SDSU) has revealed information on a heart protein that could play a critical role in the body’s ability to combat heart disease and recover from heart attack.

Study finds Evolut R TAVR device is safe, effective at 30 days in high-risk patients

A prospective, single-arm, non-randomized study found that the CoreValve Evolut R device was safe and effective in the short-term in patients with severe aortic stenosis who underwent transcatheter aortic valve replacement (TAVR).

Pages